Total de derechos de voto
MaxCyte, Inc.
("MaxCyte" o la "Compañía")
Total de derechos de voto
ROCKVILLE, MD, January 2, 2024 - MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, Anuncia that pursuant to its block admission facility, since 30 November 2023 it has issued 251,799 de acciones comunes, $0.01 par, de la Compañía ("Acciones Comunes") en satisfacción del ejercicio de opciones sobre acciones.
Derechos de voto totales
As at 31 December 2023, the total issued stock capital of the Company following the recent issue of the new Common Stock is 103,961,670 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
Para más información, por favor póngase en contacto con:
Contactos de MaxCyte: Asesor de IR de EE. UU. Grupo Gilmartin David Deuchler
|
+1 415-937-5400
| |||
Consejero Designado y Sociedad Conjunta Broker panmure gordon Emma Earl/Freddy Crossley Corretaje corporativo Rupert Dearden |
44 0 20 7886 2500 | |||
Asesor de RI del Reino Unido Consejo ICR Mary Jane Elliott chris galés |
44 0 203 709 5700
| |||
Acerca de MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT? platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx?, STx?, GTx? and VLx ?; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By Al brindarles a nuestros socios la plataforma tecnológica adecuada, así como apoyo científico, técnico y regulatorio, nuestro objetivo es guiarlos en su viaje para transformar la salud humana. Conoce más en maxcyte.com y síguenos en Twitter y Etiqueta LinkedIn.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.